EcoVadis Gold rating validates Ontex’s business sustainability commitments and performance for second year in a row Aalst, Belgium, February 19, 2026 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, announces that it has been awarded a Gold rating by EcoVadis for the second consecutive year. EcoVadis, a global leader in business sustainability assessments, awarded Ontex a higher total score year on year, placing the company in the top 3% of companies assessed globally. The recognition reflects the solid foundations Ontex has bu...
EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamheidsengagement en -prestaties van Ontex Aalst, België, 19 februari 2026 – Ontex Group NV [EURONEXT: ONTEX], een toonaangevende ontwikkelaar en producent van persoonlijke verzorgingsproducten, heeft het tweede jaar op rij een gouden medaille van EcoVadis ontvangen. EcoVadis, wereldwijd toonaangevend in duurzaamheidsbeoordelingen van bedrijven, kende Ontex een hogere totaalscore toe dan vorig jaar. Ontex behoort daarmee vandaag tot de top 3% van de wereldwijd beoordeelde bedrijven. De erkenning weerspiegelt de solide funda...
A director at X-Fab Silicon Foundries SE bought 5,500 shares at 4.390EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Barco's FY25 results were broadly in line with market expectations, demonstrating the company's ability to grow sales and margins despite a challenging macro environment. However, the performance also revealed vulnerabilities—most notably a significant decline in order intake and a sharp reduction in the order book, both of which signal weakening forward demand and warrant close attention. Cinema was the strongest division, while Healthcare underperformed. EBITDA slightly exceeded expectations,...
Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.
Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 16 February 2026, 17.45 hrs CET Melexis reports the purchase of 22,000 Melexis shares on Euronext Brussels in the period from 9 February 2026 to 13 February 2026, related to the share buy-back program announced on 10 December 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)9/2/20264,00055.3053.5055.90221,21510/2/20264,50056.9355.3557.50256,16711/2/20264,50056.3755.6556.85253,64712/2/20264,50056.1655.6557.35252,72713/2/20264,50055.9855.50...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 16 februari 2026, 17.45 uur CET Melexis meldt de aankoop van 22.000 Melexis-aandelen op Euronext Brussel in de periode van 9 februari 2026 tot 13 februari 2026, in het kader van het inkoopprogramma aangekondigd op 10 december 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)9/2/20264.00055,3053,5055,90221.21510/2/20264.50056,9355,3557,50256.16711/2/20264.50056,3755,6556,85253.64712/2/20264.50056,1655,6557,35252.72713/...
Ontex has released weak FY 2025 results. The company downgraded its guidance twice in the year, due to soft demand amid weak consumer sentiment, high promotional activity from A brands and supply-chain constraints, as well as increases in raw-material costs. Meanwhile, H2 was more challenging than management's initial expectations. Looking ahead, Ontex anticipates that market conditions will remain soft. That said, management is optimistic that performance will improve gradually through the year...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.